Patents by Inventor Edward B. Reilly

Edward B. Reilly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20230321271
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: February 22, 2023
    Publication date: October 12, 2023
    Applicants: AbbVie Biotherapeutics Inc., AbbVie Inc.
    Inventors: Christian B. Allan, Louie Naumovski, Edward B. Reilly
  • BISPECIFIC BINDING MOLECULES
    Publication number: 20220306740
    Abstract: The present disclosure provides novel bispecific molecules that binds to human Survivin and human CD3, and methods of making and using the same.
    Type: Application
    Filed: November 1, 2021
    Publication date: September 29, 2022
    Inventors: Adam S. Chervin, Feng Dong, Edward B. Reilly, Jennifer D. Stone, Michael K. White
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20220288221
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: October 20, 2021
    Publication date: September 15, 2022
    Inventors: Edward B. REILLY, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF
    Publication number: 20210312797
    Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
    Type: Application
    Filed: March 24, 2020
    Publication date: October 7, 2021
    Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. Digiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
  • BISPECIFIC BINDING MOLECULES
    Publication number: 20210253700
    Abstract: The present disclosure provides novel bispecific molecules that binds to human Survivin and human CD3, and methods of making and using the same.
    Type: Application
    Filed: February 12, 2021
    Publication date: August 19, 2021
    Inventors: Adam S. Chervin, Feng Dong, Edward B. Reilly, Jennifer D. Stone, MIchael K. White
  • PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF
    Publication number: 20210074147
    Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
    Type: Application
    Filed: March 24, 2020
    Publication date: March 11, 2021
    Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. Digiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
  • ANTI-PRLR ANTIBODY-DRUG CONJUGATES (ADC) AND USES THEREOF
    Publication number: 20210061916
    Abstract: Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.
    Type: Application
    Filed: April 6, 2020
    Publication date: March 4, 2021
    Inventors: Edward B. Reilly, Mark Anderson
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200405878
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: February 7, 2020
    Publication date: December 31, 2020
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20200215200
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: January 17, 2020
    Publication date: July 9, 2020
    Inventors: Christian B. ALLAN, Louie NAUMOVSKI, Edward B. REILLY
  • Anti-cMet antibody drug conjugates and methods for their use
    Patent number: 10603389
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: March 31, 2020
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Christian B. Allan, Louie Naumovski, Edward B. Reilly
  • ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20190314518
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: May 28, 2019
    Publication date: October 17, 2019
    Inventors: Christian B. ALLAN, Louie NAUMOVSKI, Edward B. REILLY
  • Anti-cMet antibody drug conjugates and methods for their use
    Patent number: 10383948
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: August 20, 2019
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Christian B. Allan, Mark Anderson, Louie Naumovski, Edward B. Reilly, Jieyi Wang
  • PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF
    Publication number: 20190153110
    Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
    Type: Application
    Filed: November 27, 2018
    Publication date: May 23, 2019
    Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. Digiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20190134216
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: October 8, 2018
    Publication date: May 9, 2019
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • Prolactin receptor binding proteins and uses thereof
    Patent number: 10184003
    Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: January 22, 2019
    Assignee: AbbVie Inc.
    Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. Digiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
  • ANTI-PRLR ANTIBODY-DRUG CONJUGATES (ADC) AND USES THEREOF
    Publication number: 20190010237
    Abstract: Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 10, 2019
    Inventors: Edward B. Reilly, Mark Anderson
  • Anti-PRLR antibody-drug conjugates (ADC) and uses thereof
    Patent number: 10112999
    Abstract: Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: October 30, 2018
    Assignee: AbbVie Inc.
    Inventors: Edward B. Reilly, Mark Anderson
  • Anti-EGFR antibodies and antibody drug conjugates
    Patent number: 10098968
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 16, 2018
    Assignee: Abbvie Inc.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20180250418
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: March 2, 2018
    Publication date: September 6, 2018
    Inventors: Daniel E.H. AFAR, Christian B. ALLAN, Mark ANDERSON, Louie NAUMOVSKI, Edward B. REILLY, Jieyi WANG
  • ANTI-PRLR ANTIBODY-DRUG CONJUGATES (ADC) AND USES THEREOF
    Publication number: 20180244789
    Abstract: Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.
    Type: Application
    Filed: April 6, 2018
    Publication date: August 30, 2018
    Inventors: Edward B. Reilly, Mark Anderson